TATUM-T
Clinical safety rating
cautionComprehensive clinical and safety monograph for TATUM-T (TATUM-T).
TATUM-T is a combination of ethynodiol diacetate, a progestin, and ethinyl estradiol, an estrogen. It suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation. Additionally, it increases viscosity of cervical mucus, impeding sperm penetration, and alters the endometrium to reduce implantation likelihood.
| Metabolism | Ethynodiol diacetate is rapidly deacetylated to ethynodiol and then extensively metabolized via reduction, hydroxylation, and conjugation; primary enzyme is CYP3A4. Ethinyl estradiol is metabolized primarily by CYP3A4 and undergoes phase II conjugation (glucuronidation and sulfation). |
| Excretion | Primarily renal (65-70% as unchanged drug); biliary/fecal (20-25%); minor metabolism to inactive glucuronide conjugates (<10%) |
| Half-life | Terminal elimination half-life of 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours in creatinine clearance <30 mL/min) requiring dose adjustment |
| Protein binding | 92-95% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.3-0.5 L/kg (indicating moderate tissue distribution; primarily in extracellular fluid) |
| Bioavailability | Oral: 90% (high first-pass metabolism negligible); Sublingual: 95%; Intravenous: 100% |
| Onset of Action | Oral: 0.5-1 hour; peak effect at 1-2 hours; Sublingual: 15-30 minutes |
| Duration of Action | 12-24 hours depending on dose and indication; clinical effects wane after 18 hours; dosing interval typically every 12 hours |
| Molecular Weight | 288.43 |
One tablet (ethinyl estradiol 0.035 mg / norgestimate 0.250 mg) orally once daily for 21 days, followed by 7 days of placebo.
| Dosage form | INTRAUTERINE DEVICE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min) or ESRD; use is not recommended. |
| Liver impairment | Contraindicated in Child-Pugh class C (severe hepatic impairment) and in women with active liver disease. For Child-Pugh A or B, use is not recommended due to impaired hormone metabolism. If used, monitor liver function closely. |
| Pediatric use | Not indicated for use before menarche. For post-menarche adolescents, use the same standard adult dosing regimen. Safety and efficacy established in females aged 16-35 years. |
| Geriatric use | Not indicated for use after menopause. No geriatric-specific dose adjustment is available. |
| 1st trimester | Contraindicated: teratogenic effects (e.g., masculinization of female fetus) reported. Use only if no alternative and pregnancy test confirmed negative. |
| 2nd trimester | Contraindicated: risk of fetal harm; potential for virilization of female genitalia and other teratogenic effects. |
| 3rd trimester | Contraindicated: risk of fetal harm; may cause clitoromegaly and labial fusion in female fetuses. |
Clinical note
Comprehensive clinical and safety monograph for TATUM-T (TATUM-T).
| Placental transfer | Extensive: crosses placenta readily; detectable in fetal tissues and amniotic fluid. |
| Breastfeeding | Contraindicated in breastfeeding; may cause virilization in female infants and suppress milk production via androgenic effects. |
| Lactation Rating | Avoid |
| Teratogenic Risk | TATUM-T contains cupric sulfate and zinc acetate. Copper is a required trace element but excess can be teratogenic. In animal studies, high doses of copper caused fetal malformations and embryotoxicity. In human pregnancy, therapeutic use of copper is generally not associated with major teratogenic risk when used within recommended doses. However, data are limited. For the first trimester, there is a theoretical risk of copper toxicity affecting organogenesis; for second and third trimesters, risks include potential for copper accumulation and fetal hepatic toxicity. Zinc is essential but high doses may interfere with copper absorption. Overall, use only if clearly needed. |
| Fetal Monitoring | Monitor maternal serum copper and zinc levels to avoid toxicity (copper >150 mcg/dL, zinc >100 mcg/dL). During pregnancy, monitor fetal growth via ultrasound due to theoretical risks. Check neonatal copper and zinc levels at birth if maternal use prolonged |
| Fertility Effects | No known adverse effects on fertility at therapeutic doses. Copper and zinc are essential for reproduction. However, high doses of copper may impair sperm quality in males and disrupt ovulation in females. Use within recommended doses is unlikely to affect fertility. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and with smoking (especially in women over 35 years of age). Women who use combined hormonal contraceptives should be strongly advised not to smoke.
| Serious Effects |
PregnancyBreastfeedingKnown or suspected prostate cancerSevere hepatic impairmentHypersensitivity to testosterone or any component
| Precautions | Thrombotic disorders: Venous thromboembolism, arterial thromboembolism (e.g., stroke, myocardial infarction); discontinue if symptoms occur., Hepatic disease: Discontinue if jaundice develops; use with caution in patients with impaired liver function., Risk of liver tumors (benign and malignant); discontinue if right upper quadrant pain or signs of intra-abdominal bleeding., Elevated blood pressure: Monitor and discontinue if hypertension occurs., Carbohydrate metabolism: May decrease glucose tolerance; monitor diabetic patients., Hyperkalemia: Risk in patients with renal impairment or concomitant potassium-sparing diuretics due to drospirenone component; TATUM-T does not contain drospirenone, so minimal risk., Gallbladder disease: May worsen existing disease., Hereditary angioedema: May exacerbate., Chloasma: May occur, avoid sun exposure., Retinal thrombosis: Discontinue if unexplained partial or complete vision loss. |
| Food/Dietary | No specific food interactions. Avoid excessive copper supplements as the IUD releases copper locally; systemic absorption is minimal but caution in Wilson's disease. |
| Clinical Pearls | TATUM-T is a copper-containing intrauterine device (IUD) for long-term contraception (up to 10 years). It can be used for emergency contraception if inserted within 5 days of unprotected intercourse. Mechanism involves copper-induced sperm toxicity and inhibition of implantation. May be used in nulliparous women. Counsel patients about expected bleeding pattern changes: increased menstrual flow and spotting initially. Monitor for IUD expulsion or perforation, especially postpartum. Do not use in Wilson's disease or copper allergy. |
| Patient Advice | TATUM-T provides effective contraception for up to 10 years but does not protect against STDs; use condoms for protection. · You may experience heavier periods and spotting, especially in the first 3-6 months after insertion. · Check for the IUD strings after each menstrual period to ensure it is in place. · If you miss a period or have symptoms of pregnancy, contact your healthcare provider immediately. · Insertion may cause cramps and discomfort that typically resolve within a few hours to days. · Seek medical attention if you have severe pelvic pain, foul-smelling discharge, or fever, which could indicate infection. |
Loading safety data…